Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug;39(8):3711-3734.
doi: 10.1007/s12325-022-02173-7. Epub 2022 Jun 23.

Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018

Yifei Liu  1 , Martha Skup  2 , Min Yang  3 , Cynthia Z Qi  3 , Eric Q Wu  3
Affiliations
Meta-Analysis

Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018

Yifei Liu et al. Adv Ther. 2022 Aug.

Erratum in

Abstract

Introduction: To examine the prevalence rates of biosimilar discontinuation and switchback to the originator tumor necrosis factor alpha (TNF) inhibitors following non-medical switch (NMS) in patients.

Methods: Real-world studies reporting biosimilar discontinuation and switchback rates following NMS published between January 2012 and August 2018 were identified through a systematic literature review. A meta-analysis estimated the annualized discontinuation and switchback rates. A subsequent meta-analysis assessed annualized incremental discontinuation rate among studies reporting both discontinuation rates in patients who underwent an NMS (switchers) and patients who remained on originators (non-switchers).

Results: A total of 66 publications were identified: 31 in gastroenterology, 32 in rheumatology, and 3 in both. Half of the studies reported switchback rates; only 9 studies reported discontinuation rates for both switchers and non-switchers. Across studies, the mean/range sample size of the NMS patient population was 136/9-1641; mean/range follow-up was 10/3-24 months. Annualized biosimilar discontinuation rate was 21% (95% confidence interval [CI] 18%, 25%). Switchback rate was 14% (95% CI 10%, 17%) among all NMS patients and 62% (95% CI 44%, 80%) among discontinuers. The mean/range sample size of switchers and non-switchers was 344/89-1621 and 768/19-2870, respectively; mean/range follow-up was 11/6-18 and 12/6-8 months, respectively. Annualized incremental biosimilar discontinuation rate was 18% (95% CI 4%, 31%).

Conclusion: Biosimilar discontinuation was found to be prevalent among patients who underwent an NMS from an originator TNF inhibitor to its biosimilar(s) in the real world. In addition, switchback to the originator TNF inhibitors was common following biosimilar discontinuation. Careful consideration is necessary when switching patients already on an originator TNF inhibitor to its biosimilar(s). Main limitations included the heterogeneity of the studies and the limited comparability of the data.

Keywords: Biosimilar; Discontinuation; Non-medical switch; Switchback; TNF inhibitors.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Meta-analysis of annualized discontinuation rate: all therapeutic areas
Fig. 2
Fig. 2
Meta-analysis of annualized switchback rate: all therapeutic areas
Fig. 3
Fig. 3
Meta-analysis of switchback rate among discontinued patients: all therapeutic areas
Fig. 4
Fig. 4
Meta-analysis of incremental annualized discontinuation rate: all therapeutic areas
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Biosimilars Resource Center. What are biologics? 2017. https://www.biosimilarsresourcecenter.org/faq/what-are-biologics/. Accessed 16 Oct 2020.
    1. Feldman SR, Bagel J, Namak S. Biosimilars for immune-mediated chronic diseases in primary care: what a practicing physician needs to know. Am J Med Sci. 2018;355:411–417. doi: 10.1016/j.amjms.2017.12.014. - DOI - PubMed
    1. Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015;27:55–62. doi: 10.1093/intimm/dxu102. - DOI - PMC - PubMed
    1. Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care. 2015;21:s331–s340. - PubMed
    1. Chingcuanco F, Segal JB, Kim SC, Alexander GC. Bioequivalence of biosimilar tumor necrosis factor-alpha inhibitors compared with their reference biologics: a systematic review. Ann Intern Med. 2016;165:565–574. doi: 10.7326/M16-0428. - DOI - PubMed

Publication types

LinkOut - more resources